Tejas Savant, an analyst from Morgan Stanley, maintained the Buy rating on Guardant Health (GH – Research Report). The associated price ...

The city is home to the University of California, San Francisco, which is entirely dedicated to graduate education in health and biomedical sciences as well as the University of California ...

Two brothers suspected of shooting at employees last month at a Redwood City business were taken into custody on Thursday, ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00. Tycho Peterson has given his Buy rating due to a combination ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the ...

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

MADISON, Wis., August 28, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ...